OIPE
OCT 04 2005
PATENT & TRADEMARK OFFICE

FIG. 1



FIG. 2


Percentage of beta-Lapachone in Supernatant
70
60
50
40
30
20
10
0
0
1
2
4
6
8
12
16
Concentration of HPBCD (mM)
Initial
Lyophilized

FIG. 3



FIG. 4

Cell Line	Tissue Origins	Applied Drug conc., μm		Colonies, percentage of control		
		β-Lapachone	Taxol	β-Lapachone	Taxol	β-Lapachone + Taxol
A2780DDP	Ovary	2	0.2	77 (1.1)	39 (0.8)	0
MCF-7	Breast	4	0.1	46 (1.4)	45 (0.3)	0
21MT	Breast	4	0.1	56 (5.0)	63 (7.0)	0
Skmel-28	Melanoma	4	0.1	56 (1.4)	44 (5.1)	0
HT-29	Colon	4	0.1	42 (1.4)	64 (2.5)	0
ASPC-1	Pancreas	4	0.2	45 (1.9)	71 (0.8)	0
G480	Lung	4	0.2	32 (0.3)	39 (2.6)	2 (0.1)
DU145	Prostate	4	0.2	50 (2.2)	30 (0.9)	0

FIG. 5

β-LAP/Taxol Ratio, % IC_{50}	OVCAR-3 Cell Line		MDAH 2774 Cell Line	
	% Absorbance	Significance*	% Absorbance	Significance*
0/0	100		100	
100/0	61.2		51.2	
75/25	57.6	$p < 0.05$	30.5	$p < 0.05$
60/40	59.2		32.0	$p < 0.05$
50/50	54.9	$p < 0.05$	36.2	$p < 0.05$
40/60	54.3	$p < 0.05$	35.6	$p < 0.05$
25/75	55.8		39.2	$p < 0.05$
0/100	71.0		52.6	

FIG. 6


100.0
90.0
80.0
70.0
60.0
50.0
40.0
% ABSORBANCE
0/0
100/0
75/25
60/40
50/50
40/60
25/75
0/100

FIG. 7


100.0
90.0
80.0
70.0
60.0
50.0
40.0
30.0
20.0
% ABSORBANCE
0/0
100/0
75/25
60/40
50/50
40/60
25/75
0/100

FIG. 8


110
100
90
80
70
60
50
40
30
20
10
0
Percent Survival
-1
1
10
100
Concentration, µm
A2780DDP
A2780s

FIG. 9


Mean number of tumor implants
110
100
90
80
70
60
50
40
30
20
10
0
Control
β-lapachone
Taxol
β-lapachone + Taxol

FIG. 10



FIG. 11A



FIG. 11B